An experienced trial attorney, appellate advocate, and strategic counselor, Nick brings to bear his broad expertise in intellectual property procurement, enforcement, and strategy to consistently deliver optimal solutions for his life science clients.
Nick Giove, a partner in the firm’s New York office and member of the Executive Committee, has successfully litigated intellectual property actions in district and appellate courts throughout the country. His practice focuses on all aspects of intellectual property and commercial litigation, including patent office prosecution and post-grant IPR proceedings, due diligence analyses, and regulatory and antitrust counseling. Nick has successfully litigated matters from pre-suit investigation, through discovery, trial, and appeal. His experience spans a wide array of drugs (antihemophilic biologics, corticosteroids, psychostimulants, bronchodilators, antiepileptics, estrogen); delivery systems (injectables, topical lotions and sprays, instant and modified-release oral dosage forms, transdermal patches, vaginal inserts, inhalation solutions); and diseases/disorders (hemophilia, ADHD, psoriasis, COPD, epilepsy, ulcerative colitis, dyspareunia). Nick also serves as the current Vice Chair of the Amicus Committee for the Federal Circuit Bar Association.
After graduating cum laude from Georgetown University with a degree in Chemistry and Mathematics, Nick received his law degree from the Benjamin N. Cardozo School of Law with a concentration in Intellectual Property and Communications Law. During law school, he served as a judicial law clerk to the Honorable Magistrate Judge William D. Wall of the Eastern District of New York. Following law school, he earned a postgraduate LL.M. degree in Intellectual Property from the Benjamin N. Cardozo School of Law.
- Shire Development LLC v. Teva Pharmaceuticals USA, Inc., No. 17-cv-01696 (D. Del.)
- Supernus v. TWi, No. 17-2513 (Fed. Cir.)
- Supernus v. Actavis, No. 16-1619 (Fed. Cir.)
- Supernus v. Actavis, No. 13-4740 (D.N.J)
- Supernus v. TWi, No. 15-369 (D.N.J)
- FTC Civil Investigative Demand to Shire Laboratories, Inc.
- FTC Civil Investigative Demand to Mylan Inc.
- Chiesi v. Sandoz, No. 13-5723 (D.N.J)
- Chiesi v. Exela, No. 13-1275 (D. Del.)
- Johnson Matthey v. Shire, No.09-260 (E.D. Tex.)
- Dey v. Sunovion, No. 07-2353 (S.D.N.Y.)
- Dey v. Teva, No. 09-008 (W.Va.)
- Shire v. Actavis, No. 10-484 Consol. (D.Del.)
- Shire v. Sandoz, No. 11-1110 (D. Col.)
- Shire v. Watson, No. 12-60862 (S.D. Fla.)
- Shire v. Osmotica, No. 12-904 (N.D.Ga.)
- Impax v. Shire, No. 10-8386 (S.D.N.Y.)
- Galderma v. Actavis, Nos.06-471, 08-115 (N.D. Tx.)
- "Dey v. Sunovion: Shielding Clinical Studies from § 102(b) 'Public Use' Scrutiny." Medical Research Law & Policy Report®, 2013.
- "Biologics and Biosimilars – Recent Developments", Co-Moderator, Federal Circuit Bar Association Bench & Bar Conference, June 23, 2018
- SuperLawyers® Metro Edition, 2012-Present
- Georgetown University, B.S., Chemistry, Cum Laude
- Benjamin N. Cardozo School of Law, J.D.
- Benjamin N. Cardozo School of Law, LL.M.
- New York
- Eastern District of New York
- Southern District of New York
- District of Colorado
- U.S. Court of Appeals for the Federal Circuit
- U.S. Supreme Court
- Registered to practice before the U.S. Patent and Trademark Office
- Federal Circuit Bar Association, Vice Chair of the Amicus Committee
- Sigma Xi Scientific Research Society
- American Chemical Society
- New York Intellectual Property Law Association